FDA issues a clinical hold on a Ziopharm Oncology Phase 1 trial to evaluate CD19-specific CAR-T therapies manufactured under point-of-care, and reques...
FDA issues Ortho Dermatologics a complete response letter on its NDA for Duobrii (halobetasol propionate and tazarotene) lotion and its use in treatin...
Federal Register notice: FDA announces an opportunity for public comment on an information collection extension for the agency guidance entitled Forma...
Federal Register notice: FDA has made available a draft guidance entitled Epidermolysis Bullosa (EB): Developing Drugs for Treatment of Cutaneous Mani...
University of Ottawa law professor Amir Attaran suggests that the Canadian government should look at suspending U.S. drug patents as the Trump Adminis...
Federal Register notice: FDA establishes a public docket to receive information, recommendations, and comments on matters related to its publication o...
FDA Review posts the Federal Register notices for the week ending 6/15/2018.
FDA makes available a guidance entitled Epidermolysis Bullosa (EB): Developing Drugs for Treatment of Cutaneous Manifestations.